ccunning

Just yesterday these figs were about half as big and green. Every time they ripen like this on my tree it blows me away.

Now we’re just in a race for them to finish ripening so we can harvest them before the squirrels do…

(also, if anyone has a guess on the variety I’d love to hear it. I even bought and planted the trees and still managed to lose track of the variety 🫣)

Black coffee and avocado on whole wheat toast with salt and pepper

Simple.
Classic.
Delicious.

Apple on Friday accused OpenAI of stealing secrets about products still in development, setting up a legal face-off between two of the world’s biggest tech companies.

In a lawsuit filed in U.S. District Court for the Northern District of California, the consumer tech giant said that OpenAI, a leader in artificial intelligence that has a new hardware business, had asked job candidates from Apple to share details about secret projects and to bring device components and prototypes to their interviews.

Apple also accused an OpenAI employee of downloading internal documents from a laptop owned by the iPhone maker.

OpenAI used the confidential information to approach Apple’s manufacturing partners, including asking one partner to demonstrate Apple’s technique for finishing metal on its devices, the lawsuit says.

Apple on Friday accused OpenAI of stealing secrets about products still in development, setting up a legal face-off between two of the world’s biggest tech companies.

In a lawsuit filed in U.S. District Court for the Northern District of California, the consumer tech giant said that OpenAI, a leader in artificial intelligence that has a new hardware business, had asked job candidates from Apple to share details about secret projects and to bring device components and prototypes to their interviews.

Apple also accused an OpenAI employee of downloading internal documents from a laptop owned by the iPhone maker.

OpenAI used the confidential information to approach Apple’s manufacturing partners, including asking one partner to demonstrate Apple’s technique for finishing metal on its devices, the lawsuit says.

Thinking about getting back into homebrewing after a ~9 year hiatus.

I assume the software situation as evolved significantly and I don’t even remember what I was using back then.

So what’s everyone using these days and why?

In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly’s powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration’s “compassionate use” program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News.

Lilly’s retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery.

Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods.

But according to a barebones public notice and Stat’s sources, a single person has been granted early access through the expanded access, aka “compassionate use” pathway, which is typically used to grant access to patients with a “serious or immediately life-threatening disease or condition” and who are not able to enroll in a clinical trial, often because they are too ill.

The access request was first made in April, when the person was 79 years old (Trump turned 80 on June 14). It was made by a senior clinician at the National Institutes of Health named Ranganath Muniyappa, who requested it on behalf of a patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension, which is high blood pressure in the lungs. Sources told Stat this patient had spent a year on tirzepatide, a drug that targets the GLP-1 and GIP hormones. But the patient had achieved only moderate weight loss on the drug.

At first I thought it might be unable to display mods across instances, but then for some communities mods from other instances do display just fine.

Image 1: Voyager shows comm has no mods
Image 2: Same comm in web interface shows there is a mod
Image 3: Voyager shows a comm with cross-instance mods

Seek wasn’t cooperating with an ID.

What’s the best way to deal with them?